Trade XERS stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Xeris Biopharma Holdings, Inc. (XERS) is trading at US$8.20, up 0.49% today as of Sep 18, 16:00 EDT. The company has a market capitalisation of US$1.59B. Over the past 52 weeks, XERS has traded between US$5.25 and US$10.08. On Syfe you can trade XERS with $0 commission and add it to your watchlist.
| Previous close | US$8.16 |
|---|---|
| Market cap | US$1.59B |
| P/E ratio | 33.17 |
| 52-week range | US$5.25 – US$10.08 |
| Volume | 3.88M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
Year: 2018
-- GUIDANCE: (XERS) Xeris Biopharma Expects Full Year 2026 Revenue Range $385M - $390M, vs. FactSet Est of $385.9M
Aug 6, 11:36 AM · MT Newswires
-- Earnings Flash (XERS) Xeris Biopharma Posts Q2 Loss $0.18 a Share
Aug 6, 11:34 AM · MT Newswires
-- Earnings Flash (XERS) Xeris Biopharma Holdings, Inc. Reports Q2 Revenue $92.1M, vs. FactSet Est of $90.1M
Aug 6, 11:15 AM · MT Newswires
Xeris Biopharma Holdings Insider Sold Shares Worth $383,176, According to a Recent SEC Filing
Jul 7, 9:19 PM · MT Newswires
Xeris Biopharma Appoints CEO John Shannon Board Chair
Jun 30, 11:48 AM · MT Newswires
Xeris Biopharma Holdings, Inc. (XERS) stock is trading at US$8.20, +0.49% from the previous close of US$8.16.
The market cap for Xeris Biopharma Holdings, Inc. (XERS) stock is approximately US$1.59B.
The price-to-earnings ratio for Xeris Biopharma Holdings, Inc. (XERS) is 33.17, based on the latest reported earnings.
The 52-week high for Xeris Biopharma Holdings, Inc. (XERS) stock is US$10.08.
The 52-week low for Xeris Biopharma Holdings, Inc. (XERS) stock is US$5.25.
Xeris Biopharma Holdings, Inc. (XERS) does not currently pay a dividend.
Stay on top of XERS
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
